Premium
Mir‐16 and Mir‐34a Suppress Growth of a Variety of Human Cancer Cells
Author(s) -
Jones Eyone,
Mazirka Pavel,
McNurlan Margaret A,
Brink Peter,
Caso Giuseppe
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb178
Subject(s) - transfection , apoptosis , cell growth , annexin , flow cytometry , microrna , cancer cell , cancer research , prostate cancer , cancer , cell , medicine , chemistry , microbiology and biotechnology , cell culture , biology , gene , biochemistry , genetics
MicroRNAs (miRs) can have a pivotal role in the regulation of tumor growth and progression and could represent important therapeutic agents. MiR‐16 and miR34a levels are reduced in many human cancers and have potential as tumor suppressors. The aim of this study was to test the direct effect of miR‐16 and miR34a on the growth of different types of human cancer cells. Human prostate (PC3) and breast cancer (MBA‐MD‐231) and melanoma (UACC62) cells were transfected with miR‐16 or miR34a. Cell proliferation was assessed over a 120 h period using an MTT based assay. MiR‐induced apoptosis was also evaluated in transfected PC3 cells by flow cytometry using Annexin V and PI staining. Increasing intracellular levels of miR‐16 had a profound suppressive effect on the growth of all tumor types. After 120 h cell number was decreased by 86% in PC3, by 56% in MDA‐MD‐231, and by 80% in UACC62 cells transfected with miR‐16 compared to controls (P<0.001). MiR‐34a significantly depressed growth in prostate and breast cancer cells. 120 h after transfection with mir‐34a cell number was 56% in PC3 and 66% lower in MBA‐MD‐231 cells than controls (P<0.001). No significant effect of miR‐34a was detected on melanoma cell growth. Both miRs increased apoptosis in PC3 prostate cancer cells, with miR‐16 showing a larger effect. The number of apoptotic cells increased from 6.4 % (control) to 20.5 % and 16.2% after treatment respectively with miR‐16 and miR34a. In summary, miR‐16 showed a profound suppressive effect on growth of human prostate and breast cancer, and melanoma cells. MiR34 depressed the growth of breast and prostate cancer cells but did not show a significant effect on UACC62 melanoma cells. The negative effect on growth of miR‐16 and miR‐34a on PC3 prostate cancer cells results from both suppression of cell proliferation and enhancement of apoptosis. Support or Funding Information Supported by the Stony Brook Foundation TRO‐Catacosinos Cancer Translational Researcher Award, and by the Dept. of Surgery, Stony Brook University Medical Center (Small Grant Program)